Compare CXE & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXE | SPRO |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.9M | 124.5M |
| IPO Year | N/A | 2017 |
| Metric | CXE | SPRO |
|---|---|---|
| Price | $3.82 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.9K | ★ 337.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $47,977,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.38 | $0.51 |
| 52 Week High | $3.88 | $3.09 |
| Indicator | CXE | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 46.81 |
| Support Level | $3.66 | $2.15 |
| Resistance Level | N/A | $2.44 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 70.83 | 44.40 |
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.